ADVA
13.5.2020 09:02:19 CEST | Business Wire | Press release
ADVA (FSE: ADV) and 6WIND today announced that German telecommunication carrier WiTCOM is using ADVA’s Ensemble Connector and 6WIND’s Turbo IPsec vRouter as key components of its new edge cloud platform. The open multi-vendor solution enables WiTCOM to power its smart city initiative with network functions virtualization (NFV) and universal customer premises equipment (uCPE). Built on best-of-breed technology from five leading suppliers, the solution supports the rapid and efficient rollout of IoT, video and next-generation services across WiTCOM’s IPv6 network and enables easy scalability for global deployments. Other partners in the project are Advantech, dacoso and Dell Technologies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200513005054/en/
“We took an innovative approach for an open multi-vendor solution to power our smart city initiative working with 6WIND, ADVA, Advantech, Dell Technologies and dacoso,” said Volker Bodenbach, head of technology and operations, WiTCOM. “Together we designed a secure open platform that powers edge cloud for IoT, video and next-generation services across our IPv6 network that can further be deployed worldwide across many verticals.”
WiTCOM’s new multi-vendor platform is composed of technologies optimized for edge cloud architecture. The uCPE approach brings dramatically increased efficiency and scale to the ICT service provider’s business. It also ensures that its customers benefit from ultimate choice and flexibility. Now, WiTCOM can streamline multiple virtual network functions (VNFs) on a single installation deployed close to the end customer, helping cities to digitalize their infrastructure and take advantage of the latest innovation in areas such as traffic control, surveillance and IoT.
“Our Ensemble Connector is the ideal solution for hosting and managing demanding uCPE applications. It’s now giving WiTCOM the power of the cloud along with several other benefits, such as zero-touch provisioning and platform security. It also provides access to the Ensemble Harmony ecosystem, which includes a wide variety of onboarded commercial VNFs,” commented James Buchanan, general manager, Edge Cloud, ADVA. “With its new uCPE network, WiTCOM can respond in an instant to customer demands and empower municipal networks to test out offerings and ideas. It will help accelerate the fourth industrial revolution and be a key tool in transforming cities into safer, less wasteful and more pleasant places to live.”
“6WIND’s vRouters provide the high-performance virtual routing foundation required for secure, scalable uCPE solutions,” said Eric Carmès, founder and CEO, 6WIND. “We are proud to work with WiTCOM alongside our partners ADVA, Advantech, dacoso and Dell Technologies to create an industry-leading smart city initiative for IoT, video and additional services.”
“Our task was to combine the components for this managed edge cloud solution into a finely tuned overall solution,” explained Karsten Geise, head of business and development, dacoso. “IoT via IPv6 public networks will be of great interest to many companies in the future if it meets such high security and automation requirements.”
“WiTCOM’s smart city blueprint extends the cloud infrastructure to the IoT edge, building a solid and open foundation to run innovative mobility and security services,” said James Yang, VP, Cloud-IoT Group, Advantech. “Our white box uCPE solutions help service providers like WiTCOM enable this intelligent edge with optimized platforms that provide ample computing power and rich connectivity while meeting edge environmental and mechanical constraints.”
Further information is available in this case study: https://adva.li/witcom-case-study .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at: www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200513005054/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 08:00:00 CET | Press release
Clinical and preclinical presentations reflect the company’s ongoing exploration of peripheral neuropathic pain Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greates
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom